A biomarker in type 2 diabetic patients (leukocyte telomere length) | ||
| Sohag Medical Journal | ||
| Volume 29, Issue 3., 2025, Pages 25-31 PDF (1.08 M) | ||
| Document Type: Review Article | ||
| DOI: 10.21608/smj.2025.401374.1588 | ||
| Authors | ||
| Hend M. Naguib Omar* 1; Aida Abdeen Mahmoud2; Emad Ahmed Mohammed3; Marwa Hashim4 | ||
| 1department of medical biochmeistry, Sohag university, sohag university | ||
| 2Department of Biochemistry, Faculty of Medicine, Sohag University | ||
| 3department of internal medicine, faculty of medicine, sohag university | ||
| 4Department of Biochemistry and microbiology, Facaulty of Medicine, Sohag University | ||
| Abstract | ||
| At the ends of linear chromosomes are specialized nucleoprotein structures called telomeres, which guard against the activation of DNA damage response and repair processes. In order to prevent replicative senescence, genomic instability, and cell death, a variety of factors localize to telomeres to regulate their length, shape, and function.in people. Chronic inflammation and oxidative stress accelerate telomere attribution, leading to organ deterioration and replicative senescence. Telomere length can be utilized as a potential indication of biological aging and represents the total damage caused by those exposure factors. Numerous age-related illnesses, including diabetes, heart disease, and cancer, have been connected to shorter telomere length. Therefore, finding a biomarker that could offer more details about a person's cardiometabolic health in addition to (or instead of) their chronological age would be very helpful in both predicting and preventing disease. Perhaps one of these biomarkers is telomere length. The relationship between telomere shortening and type 2 diabetes mellitus will be interpreted in this review. | ||
| Keywords | ||
| T2DM; rLTL; biomarker | ||
|
Supplementary Files
|
||
|
Statistics Article View: 60 PDF Download: 40 |
||
